Offering sells units of one share and 1.5 warrants at $1.50 per unit
By Devika Patel
Knoxville, Tenn., June 16 – Relmada Therapeutics, Inc. completed a $10.7 million private placement of units on June 19, according to an 8-K filed Monday with the Securities and Exchange Commission. Laidlaw & Co. (UK) Ltd. was the agent.
The company sold 7,129,725 units of one common share and 1.5 warrants at $1.50 per unit.
The first full warrant is exercisable at $1.50 for 120 days and the second half-share warrant is exercisable at $2.25 for five years.
The company also said it raised about $15 million in another private placement on May 15 through the same agent. The sales were associated with Camp Nine, Inc.’s going-public transaction. Camp Nine went public via a reverse merger in the form of a share exchange on May 20, in which it acquired about 94% of the outstanding shares of Relmada.
The clinical-stage company developing novel therapies for the treatment of chronic pain, formerly known as Camp Nine, Inc., is based in New York.
| Issuer: | Relmada Therapeutics, Inc.
|
| Issue: | Units of one common share and 1.5 warrants
|
| Amount: | $10,694,588
|
| Units: | 7,129,725
|
| Price: | $1.50
|
| Warrants: | 1.5 warrants per unit
|
| Warrant expiration: | 120 days, five years
|
| Warrant strike price: | $1.50, $2.25
|
| Agent: | Laidlaw & Co. (UK) Ltd.
|
| Settlement date: | June 10
|
| Stock symbol: | OTCBB: CMPE
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
